| Clinical trials in thrombolytic therapy, Part 1: Outcome markers that go beyond mortality reduction. | |
| | |
MedLine Citation:
|
PMID: 9397234 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The use of outcome markers other than mortality reduction alone for evaluating thrombolytic agents in patients with acute myocardial infarction (AMI) is discussed. Mortality has been a primary endpoint in clinical trials evaluating thrombolytic agents for treatment of AMI. However, differences in mortality rates among thrombolytics are 1% or less and require tens of thousands of patients to detect. Broadening the endpoints studied will allow for more extensive data collection and more comprehensive cost-effectiveness analysis, enabling clinicians to make better decisions. The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-1) trial measured not only mortality but issues related to the patency of the infarct-related artery and complications. Other potentially important outcome markers after AMI are left ventricular function; markers of reperfusion, such as early resolution of ST-segment elevation; and resolution of chest pain. Available long-term data show that the mortality benefit from alteplase is sustained over time and is correlated with enzymatically determined infarct size, left ventricular function, the number of diseased vessels, and Thrombolysis in Myocardial Infarction flow grade at the time of discharge from the hospital. Clinicians must also consider risk factors for stroke. Outcome measures other than mortality alone may help in determining which thrombolytic agent is most effective clinically and in financial decision-making without requiring large, expensive trials. |
| | |
Authors:
|
K A Stringer |
Related Documents
:
|
8456754 - Minimizing the risk of inappropriately administering thrombolytic therapy (thrombolysis... 3142944 - Reperfusion therapy in inferior myocardial infarction. 8269224 - Late thrombolytic therapy: mechanism of benefit and potential risk among patients treat... 2208814 - The potential for prehospital thrombolytic therapy. 15173714 - Development of biologic coronary artery bypass grafting in a rabbit model: revival of a... 2963694 - Myocardial salvage following elective angioplasty for total coronary occlusion. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists Volume: 54 Suppl 1 ISSN: 1079-2082 ISO Abbreviation: Am J Health Syst Pharm Publication Date: 1997 Nov |
Date Detail:
|
Created Date: 1998-01-15 Completed Date: 1998-01-15 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9503023 Medline TA: Am J Health Syst Pharm Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: S23-6 Citation Subset: IM |
Affiliation:
|
School of Pharmacy, University of Colorado Health Sciences Center 80262, USA. kathleen.stringer@uchsc.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cerebrovascular Disorders
/
prevention & control Clinical Trials as Topic Humans Myocardial Infarction / drug therapy*, physiopathology Plasminogen Activators / therapeutic use* Streptokinase / therapeutic use Thrombolytic Therapy* Tissue Plasminogen Activator / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
EC 3.4.-/Streptokinase; EC 3.4.21.-/Plasminogen Activators; EC 3.4.21.68/Tissue Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A fresh look at the molecular pharmacology of plasminogen activators: from theory to test tube to cl...
Next Document: Clinical trials in thrombolytic therapy, Part 2: The open-artery hypothesis and RAPID-1 and RAPID-2.